iOnctura SA

5 trials 2 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

2 Completed trials

3 Countries active

11 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase II: 1 Phase I/II: 2 Phase I: 1 Phase I (Other): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 1 Uveal melanoma 1 Ocular melanoma 1 Non-small cell lung cancer metastatic 1

Top IMPs

ROGINOLISIB 3 ANHYDROUS DOCETAXEL 1 DACARBAZINE CITRATE 1 DOSTARLIMAB 1 IPILIMUMAB 1 NIVOLUMAB 1 NIVOLUMAB, RELATLIMAB 1

All trials

5 total

First-in-Human Dose Study of IOA-244 in patients with advanced or metastatic cancers. Pending

2024-518404-44-00 Phase I 1 country
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting

2024-515252-20-00 Phase I/II 2 countries ROGINOLISIB
Phase II study of Roginolisib in UM patients Recruiting

2024-514333-37-00 Phase II 2 countries DACARBAZINE CITRATE; IPILIMUMAB; NIVOLUMAB; NIVOLUMAB, RELATLIMAB; ROGINOLISIB
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Ended

2024-517741-14-00 Phase I/II 3 countries ANHYDROUS DOCETAXEL; DOSTARLIMAB; ROGINOLISIB
Dose Escalation Phase 1 Study of IOA-289 in combination with gemcitabine/nab-paclitaxel Ended

2024-515674-27-00 Phase I (Other) 1 country

Showing 1–5 of 5 trials

← All sponsors A–Z